Clinical Trials Browser

Phase 2 × Hodgkin Disease × Everolimus × Clear all

Hodgkin Disease, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT00436618 2019-10-22

Everolimus in Treating Patients With Lymphoma That Has Relapsed or Not Responded to Previous Treatment

Burkitt Lymphoma, Hodgkin Disease, Immunoblastic Lymphadenopathy, Leukemia, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Waldenstrom Macroglobulinemia, Mycosis Fungoides, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell

NCT01022996 2016-05-18

Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.

Phase 2 Completed

57 enrolled 10 charts

Lymphoid

Hemic and Lymphatic Diseases, Hodgkin Disease, Lymphatic Diseases, Lymphoma, Lymphoproliferative Disorders, Neoplasms by Histologic Type

Clinical Trials

Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma

Everolimus in Treating Patients With Lymphoma That Has Relapsed or Not Responded to Previous Treatment

Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.